<DOC>
	<DOCNO>NCT02048384</DOCNO>
	<brief_summary>This phase 1b , multi-center , open label , randomize study evaluate safety feasibility administer metformin without rapamycin disease stabilization chemotherapy subject metastatic PDA .</brief_summary>
	<brief_title>A Study Metformin With Without Rapamycin Maintenance Therapy After Induction Chemotherapy Subjects With Pancreatic Cancer</brief_title>
	<detailed_description>Subjects metastatic PDA receive FOLFIRINOX gemcitabine-containing regimen achieve stable disease well enrol onto study . Subjects least 6 month chemotherapy decline continuation chemotherapy stable disease well 2 scan take least 6 week apart . If applicable , subject also stable decline CA19-9 . Twenty-two subject randomize 1:1 ratio metformin ( Arm A ) metformin + rapamycin ( Arm B ) . Subjects stratify accord prior chemotherapy regimen : FOLFIRINOX gemcitabine-containing regimen . Treatments administer orally 28 day cycle . Metformin administer 850mg twice daily rapamycin administer 4mg daily .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Histologically cytologically confirm metastatic pancreatic adenocarcinoma . Subjects islet cell neoplasms exclude . Subjects mixed histology exclude . Have receive 6 month chemotherapy . Have stable disease least 6 month current regimen last 2 scan take least 6 month apart . Measurable disease require . Subject lesion amenable biopsy must agree biopsy baseline 2 treatment biopsy amenable consider reasonably safe obtain . Eastern Cooperative Oncology Group performance status 0 1 . Life expectancy great 12 week . Adequate organ marrow function . Oxygen saturation room air &gt; 92 % pulse oximetry . ( Subjects intermittent continuous supplemental oxygen exclude ) . Women childbearing potential men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry duration study participation . Ability understand willingness sign write informed consent document . Receiving receive investigational agent within 28 day prior Day 1 treatment study . Has undergone major surgery , diagnostic surgery ( i.e . surgery do obtain biopsy diagnosis abort Whipple ) , within 28 day prior Day 1 treatment study . Known history brain metastasis unless previously treat well control least 3 month ( define stable clinically , edema , steroid ) . History allergic reaction attribute compound similar chemical biologic composition metformin rapamycin . Taking ketoconazole , voriconazole , itraconazole , erythromycin , telithromycin , clarithromycin , rifampin , rifabutin , bromocriptine , cimetidine , cisapride , clotrimazole , danazol , diltiazem , fluconazole , protease inhibitor ( e.g. , HIV hepatitis C include drug ritonavir , indinavir , boceprevir , telaprevir ) , metoclopramide , nicardipine , troleandomycin , verapamil , carbamazepine , phenobarbital , phenytoin , rifapentine , St. John 's Wort ( Hypericum perforatum ) , grapefruit juice . Subjects metformin exclude . Has receive nononcology live vaccine therapy use prevention infectious diseases 28 day prior initiation treatment study . Uncontrolled intercurrent illness include , limited , ongoing active infection ( bacterial , viral , fungal infection ( ) require systemic therapy ) , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Has serious medical risk factor involve major organ system Investigator considers unsafe subject receive experimental research drug . Unhealed surgical wound clinically significant wound . Known history chronic HIV , Hepatitis B hepatitis C infection . Pregnant breast feeding . Unwilling unable comply study procedure . Can reliably swallow pill .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>rapamycin</keyword>
	<keyword>metformin</keyword>
	<keyword>pancreatic cancer</keyword>
	<keyword>adenocarcinoma</keyword>
	<keyword>metastatic</keyword>
</DOC>